Ocera Therapeutics (OCRX) Tops Q3 EPS by 16c

Ocera Therapeutics (NASDAQ: OCRX) reported Q3 EPS of ($0.34), $0.16 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $233 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c